B of A Securities Maintains Buy on WAVE Life Sciences, Lowers Price Target to $21

Benzinga Newsdesk www.benzinga.com Neutral 64.9%

Neg 0% Neu 64.9% Pos 0%

B of A Securities analyst Alec Stranahan maintains WAVE Life Sciences (NASDAQ:WVE) with a Buy and lowers the price target from $38 to $21.